Biotech Values

[jbog]

BSR David

Last year the FDA approved ixabepilone for 3rd line MBC. I thought that Avastin was also approved in 2nd and 3rd line MBC and it is Avastin that is in trouble with the FDA in this area.



IXEMPRA (ixabepilone) is indicated as monotherapy for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine. This drug was approved on it's PFS and ORR basis.